SINGAPORE: According to a study published in The  Lancet Respiratory Medicine, the overall risk of myopericarditis - a kind of heart inflammation - following a Covid-19 vaccine is rare and comparable to or lower than the risk following non-Covid shots.

Researchers from Singapore's National University Hospital looked at more than 400 million immunisation doses in international databases to compare the risk of myopericarditis after vaccination against Covid-19 and other diseases including influenza and smallpox.

There was no statistically significant difference in the incidence of myopericarditis after vaccination with Covid-19. Myopericarditis was found to be 18 cases per million doses after receiving the Covid vaccine. The rate of myopericarditis was 56 instances per million doses for all other viral vaccines combined.

Dr. Kollengode Ramanathan, a cardiac intensivist at the Hospital, said, "Our research reveals that the overall risk of myopericarditis appears to be no different for this newly licenced group of vaccines against Covid- 19 compared to vaccines against other diseases."  "The risk of such uncommon incidents should be weighed against the risk of infection-related myopericarditis, and these findings should increase public trust in the safety of Covid-19 vaccines," Ramanathan said.

Myopericarditis was more common in individuals who received mRNA vaccines (22.6 cases per million doses) than in those who received non-mRNA vaccines (7.9 instances per million doses); and in those under the age of 30, males, and also after the second dosage of a Covid injection.

Lancet study finds, Booster dose cuts Omicron infection 3 days earlier than Delta

Onsite Medical Room Can Save Lives: Overview by Ziqitza Healthcare Limited

Red okra is most beneficial in summer, know the surprising benefits